Joint Venture Opportunity
OASI is seeking a joint venture partner to provide $875,000 in strategic funding to launch a specialized, physician-directed natural killer cell therapy clinic for appropriately selected international cancer patients.
Natural killer cells are an important component of the immune system’s first-line defense against cancer. Unlike conventional treatments that principally attack tumors through surgery, chemotherapy, or radiation, NK-cell therapy seeks to support the body’s ability to recognize and destroy abnormal cells. The field is supported by decades of scientific research, expanding clinical development, and substantial investment by pharmaceutical and biotechnology companies.
Most patients still cannot obtain NK-cell therapy outside limited clinical trials or expensive institutional programs. OASI is intended to address that unmet demand through a carefully structured international-treatment model that presents NK-cell therapy responsibly as an investigational adjunct—not a substitute for standard oncology care.
The initial clinic is planned for Tijuana or a comparable location in Mexico, providing convenient access for U.S. and international patients while operating within the applicable Mexican medical and regulatory framework. Qualified donor material would be obtained through approved blood-bank channels. An experienced contract laboratory would isolate, expand, test, and release the NK-cell product. The clinic would receive and store released doses, administer therapy under physician supervision, and collect standardized safety and outcomes data.
This outsourced-processing model reduces initial capital requirements, regulatory complexity, and time to revenue. Once patient volume and clinical experience justify the investment, OASI may develop or acquire controlled processing capacity to improve margins and create additional enterprise value.
Treatment programs are expected to range from approximately $30,000 to $75,000 per patient, depending on the number of infusions, dose level, clinical services, monitoring, and length of treatment. At an illustrative average revenue of $50,000 per patient, annual revenue would be approximately $2 million at 40 patients, $4 million at 80 patients, and $6 million at 120 patients. These are planning assumptions, not guarantees, and remain subject to vendor pricing, protocol selection, regulatory review, and actual patient demand.
The funding is intended to support regulatory and compliance work, clinic leasehold and buildout, qualified laboratory and blood-supply relationships, medical staffing, equipment and controlled storage, initial cell-processing commitments, patient coordination, compliant outreach, and working capital. The base plan includes a 15% startup contingency and a three-month operating reserve based on estimated monthly operating expenses of $100,000.
OASI’s objective is to build a profitable and scalable cellular-therapy enterprise while providing a more ethical alternative for patients seeking investigational care. The model emphasizes scientifically supervised treatment, transparent consent, realistic expectations, coordination with conventional oncologists, disciplined collection of safety and outcomes data, and a philanthropic access program for selected patients who could not otherwise afford treatment.
This introduction is provided solely for confidential preliminary discussion. It is not an offer to sell securities or a representation that any clinical, regulatory, or financial result will be achieved. Any investment will require definitive documentation, due diligence, applicable securities-law compliance, medical and regulatory review, and disclosure of material risks.
Review the operating model, capitalization, budget, unit economics, timeline, and principal risks.
Review the scientific evidence, manufacturing considerations, regulatory framework, and diligence materials.